ROSG.Q Stock Overview

Operates as a genomic diagnostics company worldwide. More details

ROSG.Q fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Latest financial reports are more than a year old

High level of non-cash earnings

Does not have a meaningful market cap ($5)

Shares are highly illiquid

My Notes

Capture your thoughts, links and company narrative

Rosetta Genomics Ltd. Competitors

DermTech

OTCPK:DMTK.Q

US$35.0

eFFECTOR Therapeutics

OTCPK:EFTR

US$940.0

Plant-Based Investment

OTCPK:CWWB.F

US$27.0

PLx Pharma Winddown

OTCPK:PLXP.Q

US$30.0

Price History & Performance

Summary of share price highs, lows and changes for Rosetta Genomics
Historical stock prices
Current Share Price	US$0.000001
52 Week High	US$0.0001
52 Week Low	US$0.000001
Beta	0
1 Month Change	-99.00%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	-99.00%
5 Year Change	n/a
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	ROSG.Q	US Biotechs	US Market
7D	-99.0%	-2.3%	-2.6%
1Y	n/a	-6.3%	24.5%

Return vs Industry: Insufficient data to determine how ROSG.Q performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how ROSG.Q performed against the US Market.

Price Volatility

Is ROSG.Q's price volatile compared to industry and market?
ROSG.Q volatility
ROSG.Q Average Weekly Movement	n/a
Biotechs Industry Average Movement	10.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	17.7%
10% least volatile stocks in US Market	3.1%

Stable Share Price: ROSG.Q's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine ROSG.Q's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2000	n/a	n/a	www.rosettagenomics.com

Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company’s microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests. It also provides UroVysion, a urine-based Fluorescence In Situ Hybridization (FISH) assay that is intended for use in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer; and ERG/PTEN, which are FISH-based prognostic tests in prostate cancer.

Rosetta Genomics Ltd. Fundamentals Summary

How do Rosetta Genomics's earnings and revenue compare to its market cap?
ROSG.Q fundamental statistics
Market cap	US$5.00
Earnings (TTM)	-US$9.48m
Revenue (TTM)	US$2.86m

0.0x

P/S Ratio

0.0x

P/E Ratio

Is ROSG.Q overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ROSG.Q income statement (TTM)
Revenue	US$2.86m
Cost of Revenue	US$1.90m
Gross Profit	US$962.00k
Other Expenses	US$10.45m
Earnings	-US$9.48m

Last Reported Earnings

Jun 30, 2017

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did ROSG.Q perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/02 23:27
End of Day Share Price	2024/12/27 00:00
Earnings	2017/06/30
Annual Earnings	2016/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Rosetta Genomics Ltd. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Robert LeBoyer	Aegis Capital Corporation
Michael Petusky	Barrington Research Associates, Inc.
Sung Ji Nam	Cantor Fitzgerald & Co.